Leukocyte apheresis
| Leukocyte apheresis | |
|---|---|
| Specialty | Gastrointestinal |
Leukocyte apheresis is a medical device therapy (selective
leukocytes[2] that play a key role in the inflammatory stages of ulcerative colitis (UC).[3] Selectively reducing these cells in the blood helps to reduce inflammation in the colon.[4] Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.[5]
References
- ^ "Global Medical Device Network". Archived from the original on 2014-08-15.
- PMID 21078086.
- PMID 9616306.
- S2CID 23733856.
- ^ Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO).
